While hardly groundbreaking, the four-year follow-up data of the ELEVATE-TN trial affirms our confidence that acalabrutinib is a strong choice for frontline therapy in CLL.
Ibrutinib and Venetoclax have as we like to say at the CLL Society orthogonal or complementary mechanisms of action. Ibrutinib inhibits chronic lymphocytic leukemia or CLL cells’ proliferation and gets the cancer cells out of their protective niches in the nodes and bone marrow and into the blood stream
In this paper presented at ASCO 2021 by Alrawashdh et al, we learn about historical survival trends for CLL patients over the 22 years between 1985 and 2017.
Dr. Paolo Ghia, at the European Hematology Association (EHA) 2021 virtual annual meeting, presented the results of seven years of follow-up of treatment-naïve chronic lymphocytic leukemia patients treated with ibrutinib, a once-daily Bruton’s tyrosine kinase inhibitor.
In this ASCO 2021 abstract by Ailawadhi from Mayo and others, we learn of the first in human trial of a novel BCL-2 inhibitor (BCL-2i), lisaftoclax or APG-2575.
Dr. Matt Davids of Dana Farber presented this abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021) that updated the results of combining two different oral targeted therapies that both block B-cell receptor (BCR) signaling: Ibrutinib through BTK inhibition and umbralisib, an experimental inhibitor of PI3K.
The CAPTIVATE study data has been highly anticipated. At ASH 2020, we got important results. Dr. Wierda presented the results of Minimal (Measurable) Residual Disease (MRD) cohort using MRD status to guide therapy: Undetectable MRD (uMRD) was achieved in >2/3 of patients with 12 cycles of I+V, and the
This was accepted as a late breaking abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021), reflecting its importance to the best management of relapsed/ refractory (R/R) chronic lymphocytic leukemia (CLL). Investigators from multiple CLL centers in Europe, Australia, and North America were involved in this research.